Colinz Laboratories

Colinz Laboratories AAQS

The The AAQS of Colinz Laboratories (531210.BO) as of Oct 15, 2026 is 2. In the previous year, The AAQS was 2.00 — a change of 0.00% (lower).

AAQS

2

YoY

0.00%

Last updated:

Colinz Laboratories has a current AAQS of 2.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock Colinz Laboratories in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The Colinz Laboratories AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2019
2.00 INR
Jan 1, 2020
2.00 INR
Jan 1, 2021
2.00 INR
Jan 1, 2022
2.00 INR
Jan 1, 2023
2.00 INR
Jan 1, 2024
2.00 INR
Jan 1, 2025
2.00 INR
Jan 1, 2026
2.00 INR
The Colinz Laboratories AAQS history
YEARAAQSYoY
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
2—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Colinz Laboratories Stock analysis

What does Colinz Laboratories do? Colinz Laboratories Ltd, listed on the Bombay Stock Exchange with ticker 531210.BO and ISIN INE923C01011, is a pharmaceutical company headquartered in Mumbai, India. The company operates within the Health Care sector, specifically in the Pharmaceuticals industry. It went public through an IPO on January 13, 2004. Colinz Laboratories is engaged in the manufacturing and marketing of pharmaceutical formulations across various dosage forms, including tablets, capsules, granules, liquid orals, injectables, ointments, and creams. The company's product portfolio targets several medical conditions, such as hypertension, cholesterol, diabetes, piles, pyrexia, and malaria, with specific offerings for gynecological treatments like morning sickness, infertility, intrauterine growth restriction (IUGR), and pregnancy maintenance. Additionally, it provides hematinic, antispasmodic, anti-inflammatory, anti-allergic, and medicated shampoo products. Colinz Laboratories markets its products directly within several Indian states, including Maharashtra, Karnataka, Andhra Pradesh, Gujarat, Rajasthan, Madhya Pradesh, Chhattisgarh, and West Bengal, utilizing its own marketing team. The company's website is www.colinz.com. It is important to note that the company's operations and product details are based on the provided information without additional verification. Colinz Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Colinz Laboratories stock

The AAQS of Colinz Laboratories is 2 in 2026.

On Eulerpool you can find the complete historical development of The AAQS Colinz Laboratories since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Colinz Laboratories

All Key Metrics — Colinz Laboratories